BR112015023129A2 - compostos aromáticos substituídos para o tratamento de fibrose pulmonar, fibrose hepática, fibrose da pele e fibrose cardíaca - Google Patents

compostos aromáticos substituídos para o tratamento de fibrose pulmonar, fibrose hepática, fibrose da pele e fibrose cardíaca

Info

Publication number
BR112015023129A2
BR112015023129A2 BR112015023129A BR112015023129A BR112015023129A2 BR 112015023129 A2 BR112015023129 A2 BR 112015023129A2 BR 112015023129 A BR112015023129 A BR 112015023129A BR 112015023129 A BR112015023129 A BR 112015023129A BR 112015023129 A2 BR112015023129 A2 BR 112015023129A2
Authority
BR
Brazil
Prior art keywords
fibrosis
treatment
aromatic compounds
substituted aromatic
skin
Prior art date
Application number
BR112015023129A
Other languages
English (en)
Portuguese (pt)
Inventor
Zacharie Boulos
Grouix Brigitte
Sarra-Bournet François
Bienvenu Jean-Francois
Geerts Lilianne
Gagnon Lyne
leduc Martin
Laurin Pierre
Abbott Shaun
Perron Valérie
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of BR112015023129A2 publication Critical patent/BR112015023129A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112015023129A 2013-03-15 2014-03-14 compostos aromáticos substituídos para o tratamento de fibrose pulmonar, fibrose hepática, fibrose da pele e fibrose cardíaca BR112015023129A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798427P 2013-03-15 2013-03-15
PCT/CA2014/000237 WO2014138907A1 (en) 2013-03-15 2014-03-14 Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis

Publications (1)

Publication Number Publication Date
BR112015023129A2 true BR112015023129A2 (pt) 2017-07-18

Family

ID=51535670

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023129A BR112015023129A2 (pt) 2013-03-15 2014-03-14 compostos aromáticos substituídos para o tratamento de fibrose pulmonar, fibrose hepática, fibrose da pele e fibrose cardíaca

Country Status (25)

Country Link
US (3) US9884802B2 (cg-RX-API-DMAC7.html)
EP (1) EP2970088B1 (cg-RX-API-DMAC7.html)
JP (1) JP6381557B2 (cg-RX-API-DMAC7.html)
KR (1) KR102303493B1 (cg-RX-API-DMAC7.html)
CN (1) CN105143170B (cg-RX-API-DMAC7.html)
AR (1) AR095427A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014231649C1 (cg-RX-API-DMAC7.html)
BR (1) BR112015023129A2 (cg-RX-API-DMAC7.html)
CA (1) CA2905633C (cg-RX-API-DMAC7.html)
CL (1) CL2015002725A1 (cg-RX-API-DMAC7.html)
DK (1) DK2970088T3 (cg-RX-API-DMAC7.html)
EA (1) EA031511B1 (cg-RX-API-DMAC7.html)
ES (1) ES2780825T3 (cg-RX-API-DMAC7.html)
IL (1) IL241164B (cg-RX-API-DMAC7.html)
MX (1) MX375261B (cg-RX-API-DMAC7.html)
MY (1) MY194727A (cg-RX-API-DMAC7.html)
NZ (1) NZ712745A (cg-RX-API-DMAC7.html)
PH (1) PH12015502012A1 (cg-RX-API-DMAC7.html)
PL (1) PL2970088T3 (cg-RX-API-DMAC7.html)
PT (1) PT2970088T (cg-RX-API-DMAC7.html)
SG (1) SG11201507274PA (cg-RX-API-DMAC7.html)
TW (2) TWI742541B (cg-RX-API-DMAC7.html)
UY (1) UY35401A (cg-RX-API-DMAC7.html)
WO (1) WO2014138907A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201507062B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
TWI662030B (zh) 2013-01-15 2019-06-11 英塞特控股公司 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
PL3203999T3 (pl) * 2014-10-10 2020-07-27 Liminal Biosciences Limited Podstawione związki aromatyczne i kompozycje farmaceutyczne do zapobiegania i leczenia osteoporozy
AU2015345943B2 (en) 2014-11-12 2020-03-19 Liminal Biosciences Limited Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
US10047033B2 (en) 2015-05-13 2018-08-14 Ds Biopharma Limited Compositions comprising oxo-derivatives of fatty acids and methods of making and using same
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
US10046007B2 (en) * 2015-06-24 2018-08-14 Prescient Pharma, Llc Compositions and methods for treatment of short telomere disorders
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
US20210106582A1 (en) * 2017-11-15 2021-04-15 Galapagos Nv Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
US20210205253A1 (en) * 2018-05-31 2021-07-08 The Asan Foundation Use Of Stearic Acid For Preventing Or Treating Pulmonary Fibrosis
US11820834B2 (en) 2018-07-10 2023-11-21 Novmetapharma Co., Ltd. Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease
MA53188A1 (fr) 2018-10-11 2021-12-31 Basf As Composés aromatiques et leurs utilisations pharmaceutiques
EP3890717A4 (en) * 2018-12-05 2022-08-24 Liminal Biosciences Limited USE OF SODIUM 2-(3-PENTYLPHENYL)ACETATE IN THE TREATMENT OF ALSTRÖM SYNDROME
US12480960B2 (en) 2019-01-11 2025-11-25 University Of Virginia Patent Foundation Compositions and methods for predicting lung function decline in idiopathic pulmonary fibrosis
WO2020181163A1 (en) * 2019-03-06 2020-09-10 Tobira Therapeutics, Inc. Lipid-based formulation of cenicriviroc
KR102133151B1 (ko) 2019-03-28 2020-07-13 주식회사 노브메타파마 Chp(사이클로-히스프로)를 포함하는 복막 섬유증의 예방, 개선 또는 치료용 조성물
WO2021015218A1 (ja) * 2019-07-24 2021-01-28 国立大学法人九州大学 転写関連因子を標的とする線維化疾患の予防または治療
CN112441916A (zh) * 2019-08-29 2021-03-05 广东药科大学 新型苯乙酸衍生物、其制备方法及其作为药物的用途
AU2021356346A1 (en) * 2020-10-06 2023-06-15 Pharmaceutique Ingenew Inc. Substituted aromatic compounds and pharmaceutical compositions thereof
US12053467B2 (en) * 2020-12-18 2024-08-06 NovMeta Pharma Co., Ltd. Method of treating fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20012434A1 (it) * 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
EP2427416B1 (en) * 2009-05-04 2016-03-09 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical uses thereof
BRPI1015118A2 (pt) 2009-05-04 2016-04-12 Prometic Biosciences Inc sais de ácido pentilfenilacético e usos farmacêuticos dos mesmos
CN105997967B (zh) * 2010-10-27 2019-08-23 普罗米蒂克医药Smt有限公司 用于治疗癌症的化合物和组合物
CN102070433B (zh) * 2010-12-27 2013-03-27 桂林师范高等专科学校 芳香基乙酸类衍生物的制备方法
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
AU2015345943B2 (en) * 2014-11-12 2020-03-19 Liminal Biosciences Limited Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration

Also Published As

Publication number Publication date
MY194727A (en) 2022-12-15
EP2970088A1 (en) 2016-01-20
MX375261B (es) 2025-03-06
CA2905633C (en) 2021-12-28
US20180134649A1 (en) 2018-05-17
SG11201507274PA (en) 2015-10-29
EA201591774A1 (ru) 2015-12-30
AU2014231649B2 (en) 2018-01-04
US9884802B2 (en) 2018-02-06
PH12015502012A1 (en) 2016-01-11
AU2014231649A1 (en) 2015-10-22
IL241164B (en) 2020-11-30
JP2016510769A (ja) 2016-04-11
HK1220439A1 (en) 2017-05-05
TWI689489B (zh) 2020-04-01
EA031511B1 (ru) 2019-01-31
US11267779B2 (en) 2022-03-08
TW201441185A (zh) 2014-11-01
NZ712745A (en) 2020-06-26
CN105143170A (zh) 2015-12-09
IL241164A0 (en) 2015-11-30
AU2014231649C1 (en) 2018-08-23
TW202045469A (zh) 2020-12-16
ZA201507062B (en) 2017-04-26
KR20160040452A (ko) 2016-04-14
WO2014138907A1 (en) 2014-09-18
PL2970088T3 (pl) 2020-11-02
US20160023983A1 (en) 2016-01-28
UY35401A (es) 2014-10-31
CN105143170B (zh) 2019-11-08
US20200017432A1 (en) 2020-01-16
ES2780825T3 (es) 2020-08-27
PT2970088T (pt) 2020-03-27
JP6381557B2 (ja) 2018-08-29
US10450258B2 (en) 2019-10-22
CL2015002725A1 (es) 2016-04-15
KR102303493B1 (ko) 2021-09-16
AR095427A1 (es) 2015-10-14
EP2970088A4 (en) 2016-10-19
TWI742541B (zh) 2021-10-11
DK2970088T3 (da) 2020-03-30
MX2015012886A (es) 2016-04-04
EP2970088B1 (en) 2020-01-01
CA2905633A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
PH12015502012A1 (en) Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis
MX2015011878A (es) Compuestos aromaticos sustituidos y metodo relacionado para el tratamiento de la fibrosis.
BR112014013661A8 (pt) derivados de nucleosídeos 2’,4’-difluoro-2’-metil substituídos como inibidores de replicação de hcv-rna
BR112015026410A2 (pt) derivados de dolastatina 10 e auristatinas
CY1121357T1 (el) Νεος ανοσοτροποποιητης και αντιφλεγμονωδεις ενωσεις
BR112015018738A2 (pt) compostos de tetra-hidropirrolotiazina
BR112015020545A2 (pt) derivado de tetraidroimidazo[1,5-d][1,4]oxazepina
DOP2013000239A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso.
MX2016008456A (es) Inhibidores de tirosina quinasa de bazo (syk).
BR112014007078A2 (pt) composição de controle de doença de plantas e seu uso
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112014026266A2 (pt) derivado de quinazolidinadiona
MA39189A1 (fr) Dérivés de 1h-indazole et de 1h-indole antibactériens
BR112014028718A2 (pt) derivados de hidantoína como inibidores de kv3
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
BR112015031878A2 (pt) composição farmacêutica
BRPI0815129B8 (pt) composição radiofarmacêutica, e, métodos para preparação de uma composição radiofarmacêutica
BR112015026967A2 (pt) compostos fenoxietil di-hidro-1h-isoquinolina
BR112014001369A2 (pt) derivados de ácido hidroxâmico de heteroarila e uso dos mesmos no tratamento, melhora ou prevenção de doença viral
BR112015020222A2 (pt) compostos de azetidiniloxifenilpirrolidina
BR112013001609A2 (pt) composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, uso de um composto de ciclodextrina
BR112012014196A2 (pt) agente para prevenir ou melhorar a pigmentação
BR112014032244A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças associadas com hiperplasia, neoplasia ou displasia, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
BR112015028075A2 (pt) derivado de glicinamida alfa-substituída
BR112017007420A2 (pt) compostos aromáticos substituídos e composições farmacêuticas para impedir e tratar diabetes

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PROMETIC PHARMA SMT LIMITED (CA)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements